Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Targeting inflammation in depression using Minocycline
2024-520076-10-01Phase 2Authorised
- Sponsor
- Fatebenefratelli - Provincia Lombardo Veneta
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of minocycline in major depressive disorder (MDD) and treatment-resistant depression (TRD), sponsored by Fatebenefratelli - Provincia Lombardo Veneta. Planned start Feb 2025; status: authorised.
02
Drugs
minocycline
03
Conditions
major depressive disorder (MDD)treatment-resistant depression (TRD)
Beyond the preview
Go deeper on 2024-520076-10-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520076-10-01.